Literature DB >> 6191656

Effect of anti-interferon serum of influenza virus infection in mice.

A Hoshino, H Takenaka, O Mizukoshi, J Imanishi, T Kishida, M G Tovey.   

Abstract

Mice were infected by an aerosol of influenza virus Type A (0.5 LD50) and subsequently treated with 4 intranasal instillations of anti-interferon antiserum over a period of 72 h. All the mice treated with antiserum died within 7 days post-infection, whilst the mice in the control groups survived. In mice that did not receive the antibody, virus titers in the lung peaked on day 3 and then decreased again. Also, interferon was detectable both in lung homogenates and serum. In mice treated with antiserum, no interferon was detectable and the virus concentrations in the lung increased until death. These results suggest that interferon produced in the respiratory tract plays an important role in the early stages of influenza virus infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6191656     DOI: 10.1016/0166-3542(83)90015-3

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus.

Authors:  T Utsunomiya; M Kobayashi; R B Pollard; F Suzuki
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

2.  Novel features of the respiratory tract T-cell response to influenza virus infection: lung T cells increase expression of gamma interferon mRNA in vivo and maintain high levels of mRNA expression for interleukin-5 (IL-5) and IL-10.

Authors:  N Baumgarth; L Brown; D Jackson; A Kelso
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

3.  Pulmonary deposition and clearance of aerosolized interferon.

Authors:  P R Wyde; S Z Wilson; M J Kramer; C S Sun; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

4.  Interferon alfa, infectious virus, and virus antigen secretion in respiratory syncytial virus infections of graded severity.

Authors:  C E Taylor; M S Webb; A D Milner; P D Milner; L A Morgan; R Scott; G M Stokes; A S Swarbrick; G L Toms
Journal:  Arch Dis Child       Date:  1989-12       Impact factor: 3.791

5.  Sequential infection experiments for quantifying innate and adaptive immunity during influenza infection.

Authors:  Ada W C Yan; Sophie G Zaloumis; Julie A Simpson; James M McCaw
Journal:  PLoS Comput Biol       Date:  2019-01-17       Impact factor: 4.475

6.  Assessing mathematical models of influenza infections using features of the immune response.

Authors:  Hana M Dobrovolny; Micaela B Reddy; Mohamed A Kamal; Craig R Rayner; Catherine A A Beauchemin
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

7.  Rationale for treating human influenza infections by passive transfer of specific antibodies.

Authors:  Jean-Louis Virelizier
Journal:  Influenza Other Respir Viruses       Date:  2007-03       Impact factor: 4.380

8.  A mathematical model describing the localization and spread of influenza A virus infection within the human respiratory tract.

Authors:  Christian Quirouette; Nada P Younis; Micaela B Reddy; Catherine A A Beauchemin
Journal:  PLoS Comput Biol       Date:  2020-04-13       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.